MA51432A - Procédé de préparation d'une amino-pyrimidine et de ses intermédiaires - Google Patents
Procédé de préparation d'une amino-pyrimidine et de ses intermédiairesInfo
- Publication number
- MA51432A MA51432A MA051432A MA51432A MA51432A MA 51432 A MA51432 A MA 51432A MA 051432 A MA051432 A MA 051432A MA 51432 A MA51432 A MA 51432A MA 51432 A MA51432 A MA 51432A
- Authority
- MA
- Morocco
- Prior art keywords
- intermediaries
- pyrimidine
- amino
- preparation
- Prior art date
Links
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C253/00—Preparation of carboxylic acid nitriles
- C07C253/20—Preparation of carboxylic acid nitriles by dehydration of carboxylic acid amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762610302P | 2017-12-26 | 2017-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51432A true MA51432A (fr) | 2020-11-04 |
Family
ID=67068143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051432A MA51432A (fr) | 2017-12-26 | 2018-12-26 | Procédé de préparation d'une amino-pyrimidine et de ses intermédiaires |
Country Status (15)
Country | Link |
---|---|
US (1) | US11142516B2 (fr) |
EP (1) | EP3732166A4 (fr) |
JP (1) | JP7209726B2 (fr) |
KR (1) | KR20200109314A (fr) |
CN (1) | CN112236415B (fr) |
AU (1) | AU2018397684B2 (fr) |
BR (1) | BR112020013020A2 (fr) |
CA (1) | CA3087051A1 (fr) |
EA (1) | EA202091588A1 (fr) |
IL (1) | IL275655B2 (fr) |
MA (1) | MA51432A (fr) |
MX (1) | MX2020006704A (fr) |
PH (1) | PH12020550983A1 (fr) |
SG (1) | SG11202006085PA (fr) |
WO (1) | WO2019133605A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111848423B (zh) * | 2019-04-30 | 2022-10-14 | 尚科生物医药(上海)有限公司 | 3-氧代环丁基氨基甲酸叔丁酯的制备方法 |
MA56396A (fr) * | 2019-06-27 | 2022-05-04 | Cytokinetics Inc | Polymorphes de 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)méthyl)amino)pyrimidin-5-yl)-1h-pyrrole-3-carboxamide |
WO2024064745A1 (fr) | 2022-09-21 | 2024-03-28 | Cytokinetics, Incorporated | Synthèse de reldesemtiv |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2567851A1 (fr) * | 2004-05-21 | 2006-01-05 | Merck & Co., Inc. | Modulateurs heterocycliques et carbocycliques d'amino cyclopentyle de l'activite du recepteur de la chimiokine |
MX2009012117A (es) * | 2007-05-09 | 2009-11-23 | Pfizer | Composiciones y derivados heterociclicos sustituidos y su uso farmaceutico como antibacterianos. |
AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
WO2011133920A1 (fr) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation |
ES2750751T3 (es) * | 2014-09-09 | 2020-03-27 | Astellas Pharma Inc | Composición farmacéutica novedosa para la prevención y/o el tratamiento de la incontinencia urinaria |
-
2018
- 2018-12-26 CN CN201880087986.7A patent/CN112236415B/zh active Active
- 2018-12-26 MX MX2020006704A patent/MX2020006704A/es unknown
- 2018-12-26 EP EP18897512.2A patent/EP3732166A4/fr active Pending
- 2018-12-26 AU AU2018397684A patent/AU2018397684B2/en active Active
- 2018-12-26 MA MA051432A patent/MA51432A/fr unknown
- 2018-12-26 WO PCT/US2018/067500 patent/WO2019133605A1/fr active Application Filing
- 2018-12-26 EA EA202091588A patent/EA202091588A1/ru unknown
- 2018-12-26 BR BR112020013020-6A patent/BR112020013020A2/pt unknown
- 2018-12-26 US US16/958,093 patent/US11142516B2/en active Active
- 2018-12-26 JP JP2020535626A patent/JP7209726B2/ja active Active
- 2018-12-26 KR KR1020207020649A patent/KR20200109314A/ko not_active Application Discontinuation
- 2018-12-26 SG SG11202006085PA patent/SG11202006085PA/en unknown
- 2018-12-26 CA CA3087051A patent/CA3087051A1/fr active Pending
-
2020
- 2020-06-25 IL IL275655A patent/IL275655B2/en unknown
- 2020-06-25 PH PH12020550983A patent/PH12020550983A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20200109314A (ko) | 2020-09-22 |
BR112020013020A2 (pt) | 2020-11-24 |
JP2021508702A (ja) | 2021-03-11 |
EP3732166A4 (fr) | 2021-09-01 |
EA202091588A1 (ru) | 2021-01-18 |
AU2018397684A1 (en) | 2020-07-16 |
JP7209726B2 (ja) | 2023-01-20 |
US20210061786A1 (en) | 2021-03-04 |
CA3087051A1 (fr) | 2019-07-04 |
MX2020006704A (es) | 2020-09-14 |
IL275655A (en) | 2020-08-31 |
CN112236415A (zh) | 2021-01-15 |
IL275655B2 (en) | 2023-07-01 |
US11142516B2 (en) | 2021-10-12 |
AU2018397684B2 (en) | 2023-09-07 |
WO2019133605A1 (fr) | 2019-07-04 |
EP3732166A1 (fr) | 2020-11-04 |
IL275655B1 (en) | 2023-03-01 |
CN112236415B (zh) | 2023-11-14 |
SG11202006085PA (en) | 2020-07-29 |
PH12020550983A1 (en) | 2021-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA52665A (fr) | Procédé d'amélioration de l'expression de l'hémoglobine foetale | |
MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
MD3827845T2 (ro) | Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
WO2015153889A3 (fr) | Substances et procédés pour le traitement d'une infection virale latente | |
MA51815A (fr) | Méthodes de traitement ou de prévention de migraines avec anticorps contra le receptor de cgrp | |
MA43835A (fr) | Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
TW201613880A (en) | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole | |
BR112017007012A2 (pt) | compostos anti-tnf | |
DK3668509T3 (da) | Fremgangsmåde til behandling af amyotrofisk lateralsklerose med pridopidin | |
MA45155A (fr) | Procédés de préparation d'oligomères morpholino de phosphorodiamidate | |
MA53370A (fr) | Procédé et intermédiaires pour la préparation de bilastine | |
MA42657A (fr) | Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines | |
MA50169A (fr) | Procédé de production d'un électrocatalyseur | |
MA47511A (fr) | Procédés de préparation d'ag-10, de ses intermédiaires et de sels correspondants | |
MA51432A (fr) | Procédé de préparation d'une amino-pyrimidine et de ses intermédiaires | |
ZA201900506B (en) | Processes for the preparation of 4-alkoxy-3-(acyl or alkyl)oxypicolinamides | |
MA49700A (fr) | Procédé amélioré pour la préparation de dérivés d'aminopyrimidine | |
MA42423A (fr) | Procédé de préparation d'un revêtement | |
EP3500293A4 (fr) | Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d | |
EP3261446A4 (fr) | Méthodes et compositions permettant le traitement ou la prévention de la maladie de parkinson | |
MA50124A (fr) | Procédé de préparation de tubulysines et d'intermédiaires de celles-ci | |
MA46431A (fr) | Composés et procédés pour réduire l'expression de tau | |
MA39411A (fr) | Synthèse de l'énantiomère de la progestérone et ses intermédiaires |